Creative Biolabs can offer various in vitro pharmacodynamics services to help our customers promote the development of their projects. Our technical scientists can not only save valuable time but also provide high quality and qualified service for our clients all over the world.
The biological mechanisms leading to cardiovascular disease are complex and span several key biological systems. Although advances in the prevention and treatment of cardiovascular disease have contributed to a decline in mortality rates, cardiovascular disease remains the leading cause of death all over the world. Recently, a revival of cardiovascular drug development has introduced new treatment options to the market, with several promising therapies in various stages of preclinical and clinical development. Particularly, the application of genomic technologies, as well as systems biology approaches, have collectively identified multiple potential new cardiovascular drug targets, as well as actual molecules with potential applications in cardiovascular disease.
Fig.1 Common in vitro electrophysiological methods.
For a long time in the past, classical hERG safety assay has been treated as a standard test for the evaluation of cardiovascular drug. However, studies have shown that many withdrawn drugs could block the human ether-a-go-go (hERG) channel and thus delay repolarization of the cardiac action potential and lead to prolongation of the QT interval on an electrocardiogram. What’s more, this can potentially initiate the arrhythmia known as Torsades de Pointes (TdP) with fatal consequences. Recently, a series of in vitro electrophysiological assessment assays, such as high-throughput hERG assay, rubidium flux assays, fluorescence ion channel assays using voltage-sensitive dyes, and patch-clamp assays, have been applied for in vitro pharmacodynamics study of cardiovascular drugs.
To screen safety and effective drugs for the treatment of cardiovascular diseases, we offer a package of in vitro pharmacodynamics assays, including but not limited to high-throughput hERG assay, QT prolongation assay, arrhythmogenic liability screening, and comprehensive in vitro proarrhythmia assay (CiPA). Based on advanced induced pluripotent stem cell (iPSC) technology, we also provide iPSC-based models of cardiovascular disease for drug screening.
With years of experience in this field, Creative Biolabs is capable of considerate and reliable services of high quality for our clients all over the world. Our highly experienced scientists are ready to support you with their knowledge. If you have any questions or special needs, please feel free to contact us for support. We look forward to working with you in the near future.
Reference
For Research Use Only.
